Advertisement
The Body: The Complete HIV/AIDS Resource
Sign up for free e-mail updates!The Body en Espanol
  • E-mail E-Mail
  • Printer Friendly Printable Single-Page
  • Glossary Glossary
  • Bookmark and Share Share
Henry J. Kaiser Family Foundation • International News

HIV Prevalence Rises in Swaziland Despite Efforts to Fight Disease

May 24, 2005


This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.

Toronto's Globe and Mail on Tuesday examined the "unexpected" rise in Swaziland's estimated HIV prevalence rate from 38.6% in 2002 to 42.6% in 2004 -- the highest rate in the world -- despite "massive efforts to stop the spread of the disease." African AIDS advocates said the results of the latest HIV sentinel survey conducted in 2004 among women at prenatal clinics are "shocking and devastating," according to the Globe and Mail. Following the 2002 sentinel survey, the government "poured money" into HIV/AIDS treatment and prevention, and the Global Fund To Fight AIDS Tuberculosis and Malaria has contributed about $16 million to HIV/AIDS programs in the country, the Globe and Mail reports. However, many Swazi men continue to "justify" the traditional practice of polygamy, which contributes to the spread of HIV. King Mswati III, "who holds enormous cultural influence as well as political power," has more than 12 wives, according to the Globe and Mail (Nolen [1], Globe and Mail, 5/24).

Toronto-Based Company Developing Vaginal Microbicide
The Globe and Mail on Tuesday also examined Toronto-based Polydex Pharmaceuticals' vaginal microbicide Ushercell, which was "almost inadvertently ... invented" after being "originally designed for use in processing instant-camera film" (Nolen [2], Globe and Mail, 5/24). Microbicides include a range of products such as gels, films, sponges and other products that could help prevent the sexual transmission of HIV and other sexually transmitted diseases. HIV is transmitted primarily through heterosexual intercourse in much of Africa and Asia, but no female-controlled HIV prevention method is widely available (Kaiser Daily HIV/AIDS Report, 5/4). The Eastern Virginia Medical School's CONRAD program plans to conduct a Phase III trial of Ushercell with almost 5,000 women in India and five African countries beginning next month (Nolen [2], Globe and Mail, 5/24).

Back to other news for May 24, 2005

Search the Newsroom archive

Advertisement

Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.

This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.


This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report.
  • E-mail E-Mail
  • Printer Friendly Printable Single-Page
  • Glossary Glossary
  • Bookmark and Share Share

See Also
Read More About News & Research

 

Advertisement